<?xml-stylesheet type='text/xsl' href='anzctrTransform.xsl'?>
<ANZCTR_Trial requestNumber="364221">
  <stage>Registered</stage>
  <submitdate>10/05/2013</submitdate>
  <approvaldate>15/05/2013</approvaldate>
  <actrnumber>ACTRN12613000544774</actrnumber>
  <trial_identification>
    <studytitle>Probiotic dietary supplement and stool evaluation to improve ileal pouch health</studytitle>
    <scientifictitle>Patients with an ileal pouch for ulcerative colitis taking a probiotic for 8 weeks as an open label phase one study to assess its effect on pouch function, quality of life, and to evaluate any alteration in stool microbiota.</scientifictitle>
    <utrn> U1111-1142-8913</utrn>
    <trialacronym />
    <secondaryid>Nil</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Pouchitis</healthcondition>
    <healthcondition>Ulcerative colitis</healthcondition>
    <conditioncode>
      <conditioncode1>Oral and Gastrointestinal</conditioncode1>
      <conditioncode2>Inflammatory bowel disease</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>A freeze dried probiotic powder taken in one gelatin capsule taken twice a day for 8 weeks. Each capsule will contain 10^9 colony-forming units of (bacterium name) per capsule.

To monitor compliance at the end of 8 weeks all participants will be asked to return the dispensing container with any unused capsules.</interventions>
    <comparator> No control</comparator>
    <control>Uncontrolled</control>
    <interventioncode>Treatment: Other</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>Clinical measure of pouch function using clinical portion of the Pouchitis Disease Activity Index.</outcome>
      <timepoint>after 8 weeks of probiotic</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>Quality of life using Short Form 12.</outcome>
      <timepoint>After 8 weeks of probiotic.</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Presence of probiotic in stool</outcome>
      <timepoint>weeks 0, 1, 2, 4, 8, and 3 weeks post treatment</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>DNA profile of selected bacteria</outcome>
      <timepoint>weeks 0, 1, 2, 4, 8, and 3 weeks post treatment</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Faecal calprotectin</outcome>
      <timepoint>weeks 0, 1, 2, 4, 8, and 3 weeks post treatment</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>Functioning ileal J pouch for ulcerative colitis</inclusivecriteria>
    <inclusiveminage>18</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage>90</inclusivemaxage>
    <inclusivemaxagetype>Years</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>unable to provide informed consent
</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation>Non-randomised trial</allocation>
    <concealment>Allocation is not concealed.</concealment>
    <sequence>not applicable</sequence>
    <masking>Open (masking not used)</masking>
    <assignment>Single group</assignment>
    <designfeatures />
    <endpoint>Safety</endpoint>
    <statisticalmethods />
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Phase 1</phase>
    <anticipatedstartdate>1/07/2013</anticipatedstartdate>
    <actualstartdate />
    <anticipatedenddate>29/11/2013</anticipatedenddate>
    <actualenddate />
    <samplesize>20</samplesize>
    <actualsamplesize />
    <recruitmentstatus>Not yet recruiting</recruitmentstatus>
    <recruitmentcountry>,Outside</recruitmentcountry>
    <recruitmentstate />
    <countryoutsideaustralia>
      <country>New Zealand</country>
      <state />
    </countryoutsideaustralia>
  </recruitment>
  <sponsorship>
    <primarysponsortype>University</primarysponsortype>
    <primarysponsorname>University of Otago</primarysponsorname>
    <primarysponsoraddress>Department of Surgical Sciences
Private Bag 56
Dunedin 9054</primarysponsoraddress>
    <primarysponsorcountry>New Zealand</primarysponsorcountry>
    <fundingsource>
      <fundingtype>Hospital</fundingtype>
      <fundingname>Colorectal Trust Fund
Dunedin Public Hospital</fundingname>
      <fundingaddress>Dunedin Public Hospital
Great King Street
Dunedin 9054</fundingaddress>
      <fundingcountry>New Zealand</fundingcountry>
    </fundingsource>
    <fundingsource>
      <fundingtype>University</fundingtype>
      <fundingname>Otago Innovation Ltd
University of Otago</fundingname>
      <fundingaddress>University of Otago
Private Bag 56
Dunedin 9054</fundingaddress>
      <fundingcountry>New Zealand</fundingcountry>
    </fundingsource>
    <secondarysponsor>
      <sponsortype>Hospital</sponsortype>
      <sponsorname>Dunedin Public Hospital
</sponsorname>
      <sponsoraddress>Department of Surgery
Great King Street
Dunedin 9054</sponsoraddress>
      <sponsorcountry>New Zealand</sponsorcountry>
    </secondarysponsor>
  </sponsorship>
  <ethicsAndSummary>
    <summary>An ileal pouch is formed when the end of the small bowel is used to create a pouch and anastomosed to the anus.
This is required in patients who need removal of all their colon and rectum, most commonly for ulcerative colitis.
The ileal pouch mucosa (or lining) exists in a state of a varying degree of chronic inflammation. When this is more
severe clinical pouchitis develops. Pouchitis is most likely due to an alteration in the microbiota that the ileal
mucosa is exposed to. The microbiota alter due to increased stasis of the contents of the ileal pouch, compared to
ileum in the normal state. From our previous research and that of others, certain bacteria are associated with less
inflammation and certain with more inflammation. We have selected a bacterial culture from previous research that
is associated with a healthy pouch. We have been able to develop this bacterium into a probiotic. We wish to use
this probiotic as a dietary supplement to see if we can improve the health, function and quality of life in ileal pouch
patients.</summary>
    <trialwebsite />
    <publication />
    <ethicsreview>Not yet submitted</ethicsreview>
    <publicnotes />
    <ethicscommitee>
      <ethicname>Southern Health and Disability Ethics Committee</ethicname>
      <ethicaddress>Ministry of Health
No 1 The Terrace
PO Box 5013
Wellington 6145</ethicaddress>
      <ethicapprovaldate />
      <hrec />
      <ethicsubmitdate>21/06/2013</ethicsubmitdate>
      <ethiccountry>New Zealand</ethiccountry>
    </ethicscommitee>
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title>A/Prof</title>
      <name>Mark Thompson-Fawcett</name>
      <address>Department of Surgical Sciences
University of Otago
Private Bag 56
Dunedin 9054</address>
      <phone>+64 3 4740999</phone>
      <fax>+64 3 4709677</fax>
      <email>mark.thompsonfawcett@otago.ac.nz</email>
      <country>New Zealand</country>
      <type>Principal Investigator</type>
    </contact>
    <contact>
      <title>Ms</title>
      <name>Lesley Reeves</name>
      <address>Department of Surgical Sciences
University of Otago
Private Bag 56
Dunedin 9054</address>
      <phone>+64 3 4740999 ext 8847</phone>
      <fax>+64 3 4709677</fax>
      <email>lesley.reeves@otago.ac.nz</email>
      <country>New Zealand</country>
      <type>Public Queries</type>
    </contact>
    <contact>
      <title>A/Prof</title>
      <name>Mark Thompson-Fawcett</name>
      <address>Department of Surgical Sciences
University of Otago
Private Bag 56
Dunedin 9054</address>
      <phone>+64 3 4740999</phone>
      <fax>+64 3 4709677</fax>
      <email>mark.thompsonfawcett@otago.ac.nz</email>
      <country>New Zealand</country>
      <type>Scientific Queries</type>
    </contact>
    <contact>
      <title>A/Prof</title>
      <name>Mark Thompson-Fawcett</name>
      <address>Department of Surgical Sciences
University of Otago
Private Bag 56
Dunedin 9054</address>
      <phone>+64 3 4740999</phone>
      <fax>+64 3 4709677</fax>
      <email>mark.thompsonfawcett@otago.ac.nz</email>
      <country>New Zealand</country>
      <type>Updating Information</type>
    </contact>
  </contacts>
</ANZCTR_Trial>